WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > STATE TELEHEALTH LAWS & REIMBURSEMENT POLICIES
November 2, 2018
I'm For Real
Enter your details once to access all our information and resources
Nephron Pharmaceuticals Corporation is a mid-sized company that manufactures generic respiratory medications. NPC sells to many classes of trade, including.
whitePaper | February 16, 2023
Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.
whitePaper | February 20, 2023
Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.
whitePaper | September 8, 2022
Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.
whitePaper | April 1, 2022
In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.
whitePaper | November 1, 2022
Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.
whitePaper | May 22, 2021
One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE